Ann Dermatol.  2019 Jun;31(3):335-338. 10.5021/ad.2019.31.3.335.

Omalizumab as a Succesfull Therapy in Normocomplementemic Urticarial Vasculitis: A Series of Four Patients and Review of the Literature

Affiliations
  • 1Department of Dermatology and Venereology, Okmeydanı Training and Research Hospital, Istanbul, Turkey. ecenuryksel@gmail.com

Abstract

Urticarial vasculitis is an eruption characterized by inflamed itchy or painful red papules or plaques that resemble urticaria but last longer than 24 hours and heal with residual pigmentation or purpura. Histopathologically, urticarial vasculitis presents as leukocytoclastic vasculitis with perivascular infiltrate and fibrin deposits. The treatment options are oral antihistamines, oral corticosteroids, dapsone, colchicine and hydroxychloroquine. We report four cases with normocomplementemic urticarial vasculitis who were treated with omalizumab and a brief review of the literature on the use of omalizumab in normocomplementemic urticarial vasculitis.

Keyword

Omalizumab; Urticarial vasculitis

MeSH Terms

Adrenal Cortex Hormones
Colchicine
Dapsone
Fibrin
Histamine Antagonists
Humans
Hydroxychloroquine
Omalizumab*
Pigmentation
Purpura
Urticaria
Vasculitis*
Adrenal Cortex Hormones
Colchicine
Dapsone
Fibrin
Histamine Antagonists
Hydroxychloroquine
Omalizumab
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error